Navigation Links
ARUP Laboratories' Scientist Tanya Sandrock Receives NIH Grant to Search for Additional HIV Therapies
Date:9/9/2009

SALT LAKE CITY, Sept. 9 /PRNewswire/ -- ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that ARUP's Tanya Sandrock, PhD, Research & Development scientist, received a prestigious National Institutes of Health (NIH) grant to research additional HIV therapies. Sandrock also serves as chief scientific officer of Integratech Proteomics, a University of Utah start-up company focused on developing new peptide and small-molecule therapeutics with activity against HIV integrase, an enzyme with an essential function in the retroviral replication cycle.

The NIH grant received by Sandrock aims to obtain a small molecule that mimics the effects of an HIV integrase peptide inhibitor. "Forty million people are estimated to be infected with HIV/AIDS worldwide, and 22 million people have died since the discovery of the virus in the 1980s," explained Sandrock. "Drugs that inhibit reverse transcriptase, protease, and integrase are available, but drug side effects and viral resistance have made it necessary to develop new treatments for HIV/AIDS. The inhibitory peptide, in conjunction with yeast two-hybrid technology, may result in the discovery of new INT inhibitory compounds to integrase."

Sandrock's research aims to optimize target-peptide displacement assays; screen chemical libraries under high throughput conditions for compounds that disrupt peptide-HIV integrase interaction in yeast; and select the best small-molecular weight drug candidates for further optimization.

ARUP will provide Integratech Proteomics with access to a wet lab and equipment through its incubator program, which allows research and development activities to take place on-site.

"ARUP is fully committed to maintaining its role as a training and research laboratory of the University of Utah School of Medicine," said ARUP Laboratories' President and CEO Edward Ashwood, MD. "ARUP enthusiastically supports Dr. Sandrock in her research efforts. Her persistence in pursuit of a new HIV therapeutic has been impressive. Even though AIDS has been checked by the development of drugs that target the virus, more drugs are needed to control the worldwide spread of this infection."

Integratech Proteomics benefited from a new program called Venture Bench, created by the Technology Commercialization Office (TCO) at the University of Utah, to assist university start-ups with infrastructure support. Danuta Petelenz, TCO business manager, said, "This is exactly the type of company the university is interested in assisting and starting, one that provides the possibility of a life-changing solution for a deadly disease and complements the strengths of the life-science capabilities at the University of Utah."

Integratech Proteomics will consider peptide therapy in addition to the small-molecule approach. Sandrock will examine novel nano-technology for drug delivery and will continue collaborating with the NIH, ARUP Laboratories, and the University of Utah to expand knowledge of HIV biology.

About ARUP Laboratories

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. ARUP offers over 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays, for patients nationwide. ARUP is a worldwide leader in innovative laboratory research and development. Further information on ARUP Laboratories can be found at www.aruplab.com.


'/>"/>
SOURCE ARUP Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
5. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
6. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
7. Mesa Laboratories Names New Vice President of Sales and Marketing
8. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. JDRF partners with Housey Pharmaceutical Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... property taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, ... many overseas retirement havens have extremely low property-tax rates, which contributes to the ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology: